Transformational cell therapies for patients with pancreatic disease

Koligo is dedicated to advancing R&D and technologies to cure pancreatic disease.

The people, science and innovative mindset
to forever improve the lives of people we touch.

LEADERSHIP TEAM

Matthew Lehman, Chief Executive Officer

  • Proven biotech & cell therapy executive
  • NASDAQ-listed Prima Biomed, CSE-listed M Pharmaceutical, private CRO SPRI Clinical Trials
  • Clinical research & manufacturing scale-up expertise
  • MS Columbia; BA Louisville

Balamurugan N. Appakalai, PhD, Chief of Manufacturing

  • 20+ years experience in islet cell isolation; 800 human & 600 pig pancreases
  • 100+ peer reviewed articles & presentations
  • Director of Islet Cell Lab at Cardiovascular Innovation Institute, Louisville
  • Previous islet processing at Universities of Minnesota, Colorado in Denver, Pittsburgh

Mike Hughes, MD, Chief Medical Officer

  • Director of Pancreas Transplantation, Assistant Professor of Surgery, Louisville
  • Initiated TP-IAT program in Louisville
  • 20 clinical TP-IAT performed to date & negotiated reimbursement
  • MD Wake Forest, residency at Virginia Medical Center, fellowship at University of Minnesota

Stuart Williams, PhD, Chief Technology Officer

  • Division chief, Bioficial Heart, Cardiovascular Innovation Institude
  • 300+ publications & 16 issued US patents in cell & tissue engineering
  • Experienced academic-industry partner: founded three biotech companies
  • PhD cell biology University of Delaware, postdoc Yale School of Medicine

David Blanford, Chief Operating Officer

  • Experienced financial executive for manufacturing and clinical companies
  • Managed private-equity investment, government grants, venture capital investment
  • BS Oral Roberts

Ariel Sivikofsky, Chief Finanical Officer

  • Chartered Accountant (FCA) and graduate member of the Australian Institute of Company Directors (GAICD)
  • Experienced biotech executive for private and public entities in both Australia and Europe
  • BC University of Wollongong

Peter James, Non-Executive Chairman

  • 30+ years’ experience in emerging technologies
  • Extensive experience as Chair, Non-Executive Director and CEO of both publicly listed and private companies

Jethro Marks, Non-Executive Director

  • Co-founder and CEO of The Nile and Mercury Retail, a leading Australian eCommerce service provider
  • 15+ years’ experience in marketing

Robert Clisdell, Non-Executive Director

  • Head of Bergen Capital LLC Australian office
  • Extensive experience as director for publicly traded corporations
  • 15+ years’ experience in banking, finance and accounting as an investment banker with Credit Suisse and Caliburn Partnership
  • Graduate Diploma in Applied Finance and Investment from FINSIA

Kyslecel personalized cell therapy for chronic pancreatitis. Because pain should not define your life.